HealthCor Management L.P. purchased a new stake in shares of Edwards Lifesciences Corp (NYSE:EW) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 453,715 shares of the medical research company’s stock, valued at approximately $78,992,000. Edwards Lifesciences accounts for about 2.6% of HealthCor Management L.P.’s holdings, making the stock its 18th biggest holding. HealthCor Management L.P. owned 0.22% of Edwards Lifesciences as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Honkamp Krueger Financial Services Inc. bought a new position in Edwards Lifesciences in the 3rd quarter worth $106,000. SRS Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 317.5% in the 3rd quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock worth $116,000 after purchasing an additional 508 shares during the period. TLP Group LLC raised its holdings in Edwards Lifesciences by 163.6% in the 3rd quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock worth $118,000 after purchasing an additional 422 shares during the period. LFA Lugano Financial Advisors SA bought a new position in Edwards Lifesciences in the 3rd quarter worth $121,000. Finally, Prime Capital Investment Advisors LLC raised its holdings in Edwards Lifesciences by 577.9% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 705 shares of the medical research company’s stock worth $123,000 after purchasing an additional 601 shares during the period. 82.50% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on the company. Zacks Investment Research cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, October 25th. Barclays set a $143.00 price target on Edwards Lifesciences and gave the stock a “sell” rating in a research note on Wednesday, October 24th. Raymond James increased their price target on Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “outperform” rating in a research note on Thursday, December 6th. Cowen set a $190.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Friday, November 30th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $150.00 to $157.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. Edwards Lifesciences has a consensus rating of “Buy” and an average target price of $162.85.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. The firm had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.84 earnings per share. Analysts expect that Edwards Lifesciences Corp will post 4.7 EPS for the current year.
In other news, VP Huimin Wang sold 33,800 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $150.43, for a total transaction of $5,084,534.00. Following the completion of the transaction, the vice president now owns 81,665 shares in the company, valued at $12,284,865.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Monday, October 29th. The shares were sold at an average price of $140.74, for a total value of $4,630,346.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 142,456 shares of company stock valued at $21,146,590. Company insiders own 1.84% of the company’s stock.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Featured Story: What is a conference call?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.